Table 3 Univariate and multivariate analysis of PRS

Age (> 50 vs. ≤ 50)

0.436–1.695

FIGO stage

 I + II vs. III + IV

0.875–3.124

Histology

 NECC vs. Mixed NECC

0.408–1.641

 Tumor size (≤ 4 cm vs. > 4 cm)

0.511–2.476

 Invasion (Deep vs. shallow)

1.025–1.847

 LVSI

0.646–11.806

 Nerve invasion

0.765–4.249

 PLNM

0.739–2.677

 Syn

0.014–38,678.493

 cgA

0.606–2.777

 CD56

0.625–11.030

Primary treatment

 Cycles of chemotherapy (< 4 vs. ≥ 4)

0.356–1.928

 Radiation

0.733–2.740

 Lung recurrence

0.382–1.484

 Abdominal organs recurrence

1.230–4.586

1.089–5.937

 Pelvic organs recurrence

1.017–3.760

 Bone recurrence

0.914–4.775

 Cervicothoracic lymph node recurrence

0.350–2.303

 Brian recurrence

0.453–3.645

 Vaginal vault recurrence

0.070–1.222

 Number of recurrent sites (1 vs. > 1)

1.033–1.963

1.064–2.484

Treatment after recurrence

 Antiangiogenic therapy

0.146–1.601

 ICI therapy

0.103–1.133